Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cryo Cell International (CCEL) Common Equity (2016 - 2026)

Cryo Cell International's Common Equity history spans 17 years, with the latest figure at -$18.4 million for Q1 2026.

  • Quarterly results put Common Equity at -$18.4 million for Q1 2026, down 25.55% from a year ago — trailing twelve months through Feb 2026 was -$18.4 million (down 25.55% YoY), and the annual figure for FY2025 was -$18.6 million, down 40.78%.
  • Common Equity for Q1 2026 was -$18.4 million at Cryo Cell International, up from -$18.6 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $4.4 million in Q2 2022 to a low of -$18.6 million in Q4 2025.
  • The 5-year median for Common Equity is -$10.3 million (2024), against an average of -$7.9 million.
  • The sharpest move saw Common Equity surged 350.8% in 2022, then plummeted 59040.98% in 2024.
  • Year by year, Common Equity stood at -$1.5 million in 2022, then tumbled by 623.69% to -$11.0 million in 2023, then fell by 19.81% to -$13.2 million in 2024, then plummeted by 40.78% to -$18.6 million in 2025, then grew by 1.11% to -$18.4 million in 2026.
  • According to Business Quant data, Common Equity over the past three periods came in at -$18.4 million, -$18.6 million, and -$14.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.